GE Capital Healthcare Financial Services, an operating unit of
General Electric Company
), recently acted as the lender for a term loan worth $9 million
for privately-held medical device company Cerapedics, Inc. The
transaction will likely enhance the liquidity of Cerapedics and
facilitate its working capital requirements to fuel further growth.
Colorado-based Cerapedics is a premier orthobiologics company
focused on developing and commercializing proprietary synthetic
small peptide (P-15) technology platform called i-FACTOR. This
technology platform utilizes a small peptide as an attachment
factor to stimulate the natural bone healing process and is
reportedly the only biologic bone graft available in the world. The
mechanism supports safer and more predictable bone formation at a
lower cost compared to commercially available bone growth factors.
Cerapedics is currently enrolling patients in a clinical trial in
the U.S. to assess the safety and effectiveness of P-15 Bone Putty.
This orthobiologics company will utilize a significant portion of
its enhanced liquidity to fund the regulatory process.
Serving over 100 million customers worldwide, General Electric is
one of the largest and the most diversified technology and
financial services corporations in the world, with products and
services ranging from aircraft engines, power generation, water
processing, and security technology to medical imaging, business
and consumer financing, media content and industrial products. Its
segments include Power & Water, Oil & Gas, Energy
Management, Aviation, Healthcare, Transportation, Home &
Business Solutions and GE Capital.
With more than $65 billion debt financing transactions in the last
10 years across 45 healthcare sectors, GE Capital Healthcare
Financial Services has an in-depth industry know-how and expertise
as a reliable debt provider.
General Electric currently has a Zacks Rank #3 (Hold). Other stocks
that look promising and are worth considering now in the industry
Icahn Enterprises, L.P.
Carlisle Companies Inc.
). While Icahn carries a Zacks Rank #1 (Strong Buy), both Carlisle
and ITT carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
CARLISLE COS IN (CSL): Free Stock Analysis
GENL ELECTRIC (GE): Free Stock Analysis Report
ICAHN ENTERPRIS (IEP): Get Free Report
ITT CORP (ITT): Free Stock Analysis Report
To read this article on Zacks.com click here.